That vaccine, based on an adenovirus vector, was also registered before Phase 3 trials. A trial involving 40,000 participants is now underway in Moscow.
A large-scale human trial of EpiVacCorona is likely to begin in November or December, the TASS news agency cited the consumer safety watchdog Rospotrebnadzor, which oversees the institute, as saying this month.
Hundreds of people in professions that put them at high risk of coronavirus infection have now also received the Gamaleya jab, according to the health ministry, but the vaccine is not yet in general use.
Since the start of the pandemic, Russia has recorded more than 1,340,000 infections, fourth in the world behind the United States, India and Brazil.
Another Russian Covid-19 vaccine is being developed by the Chumakov Institute in St Petersburg. It plans to start an early-stage clinical trial involving around 300 people on October 19.
(Writers: Gabrielle Tétrault-Farber, Polina Ivanova | Editor: Kevin Liffey)